| ANIMAL | evidence | Preventative semaglutide and tirzepatide treatment does not alter disease progression in the 5xFAD mouse model of Alzheimer's disease. | Semaglutide | Cognition & memory · animal | 2026-07-21 |
| ANIMAL | evidence | The Crunchometer, a low-cost, open-source acoustic analysis of feeding microstructure. | Ozempic | animal | 2026-07-14 |
| ANIMAL | evidence | The weight-loss-independent hepatoprotective benefits of semaglutide are orchestrated by intrahepatic sinusoidal endothelial GLP-1 receptors. | Semaglutide | Weight & fat loss · animal | 2026-07-07 |
| ANIMAL | evidence | Enhanced Stability and Transdermal Delivery of Semaglutide Using an L-Arginine Based Dissolving Microneedle System. | Semaglutide | animal | 2026-07-02 |
| ANIMAL | evidence | Semaglutide ameliorates aortic endothelial cell dysfunction in sarcopenia through the SIRT1/cGAS-STING signaling axis. | Semaglutide | Longevity & cellular aging · animal | 2026-07-01 |
| ANIMAL | evidence | Semaglutide ameliorates neuroinflammation and cognitive impairment in APP/PS1 mice. | Semaglutide | Cognition & memory · animal | 2026-07-01 |
| ANIMAL | evidence | GLP-1 Receptors Are Enriched in the Lymphatic Endothelium and Their Pharmacological Activation With Semaglutide Improves the Pumping Capacity of Lymphatic Vessels. | Semaglutide | animal | 2026-07-01 |
| ANIMAL | evidence | Transcriptomics of S3 segment in mice: response to type 1 diabetes, SGLT1/2 inhibition, or GLP1 receptor agonism. | Semaglutide | Glycemic control · animal | 2026-07-01 |
| ANIMAL | evidence | OGT Ameliorates Diabetes-Associated Cognitive Decline via Modulation of DRP1 Function and Mitochondrial Homeostasis. | Semaglutide | animal | 2026-07-01 |
| ANIMAL | evidence | Semaglutide Modulates Visceral Adipose Tissue Lipid Metabolism in Type 2 Diabetic Mice: A Lipidomics Study. | Semaglutide | Glycemic control · animal | 2026-06-22 |
| ANIMAL | evidence | Semaglutide Selectively Improves Metabolic and Cognitive Function in 5xFAD Mice. | Semaglutide | Cognition & memory · animal | 2026-06-11 |
| ANIMAL | evidence | Semaglutide attenuates neuroinflammation in male mice. | Semaglutide | Inflammation · animal | 2026-06-09 |
| ANIMAL | evidence | 15-PGDH inhibition promotes muscle repair and strength recovery during GLP-1 receptor agonist-induced weight loss. | Semaglutide | Weight & fat loss · animal | 2026-06-09 |
| ANIMAL | evidence | Semaglutide alleviates age-related dry eye disease by restoring lacrimal gland structure and function. | Semaglutide | Longevity & cellular aging · animal | 2026-06-01 |
| ANIMAL | evidence | Combination therapy with clinically approved PPARalpha/delta/gamma subtype-selective agonists pemafibrate, seladelpar, and pioglitazone in a 4-week diet-induced early-stage MASLD mouse model. | Semaglutide | Liver health · animal | 2026-06-01 |
| ANIMAL | evidence | Semaglutide drives weight loss through cAMP-dependent mechanisms in GLP1R-expressing hindbrain neurons. | Semaglutide | Weight & fat loss · animal | 2026-06-01 |
| ANIMAL | evidence | Gut-Derived FGF15 Modulates Lean Mass, Bone, and Bile Acid Responses to Weight Loss. | Semaglutide | animal | 2026-06-01 |
| ANIMAL | evidence | Therapeutic efficacy, biomarker signatures, and translatability of semaglutide in the liver biopsy-confirmed GAN DIO-MASH mouse model. | Semaglutide | Weight & fat loss · animal | 2026-06-01 |
| ANIMAL | evidence | Repeated semaglutide treatment attenuates cocaine-vs-food choice in male and female rats. | Semaglutide | Weight & fat loss · animal | 2026-06-01 |
| ANIMAL | evidence | Cycling GLP-1 receptor agonist treatment induces therapeutic resistance and increased adiposity. | Semaglutide | Weight & fat loss · animal | 2026-05-22 |
| ANIMAL | evidence | Insulin and Incretin Receptor Agonists Reciprocally Alter Their Blood-Brain Barrier Permeabilities. | Semaglutide | Glycemic control · animal | 2026-05-21 |
| ANIMAL | evidence | Glycemia shifts pancreatic islet rhythmicity by influencing interactions between delta cells and alpha cells. | Semaglutide | Glycemic control · animal | 2026-05-20 |
| ANIMAL | evidence | Modulation of mRNA Expression of Biomarkers in the UPR-PERK Pathway by Ellagic Acid in Metabolic Dysfunction-Associated Fatty Liver Disease. | Semaglutide | Liver health · animal | 2026-05-17 |
| ANIMAL | evidence | Differential effects of semaglutide and colchicine on atrial remodeling in rats with reduced ejection fraction after myocardial infarction. | Semaglutide | Inflammation · animal | 2026-05-06 |
| ANIMAL | evidence | 9.4-T MRI monitoring of early MASH progression and therapeutic response in a prefibrotic mouse model. | Semaglutide | Liver health · animal | 2026-05-06 |
| ANIMAL | evidence | Phyllanthus niruri niosomes ameliorate obesity-induced hepatic steatosis in rats via modulating MALAT1/miR-206/GLP-1R signaling and hepatic lipid metabolism. | Semaglutide | Weight & fat loss · animal | 2026-04-27 |
| ANIMAL | evidence | Neuroprotective Effects of Semaglutide in Cyclophosphamide-Induced Neuropathy: Restoring SIRT1/AMPK, PI3K/AKT/mTOR, and Antioxidant Pathways. | Semaglutide | animal | 2026-04-27 |
| ANIMAL | evidence | Semaglutide reduces murine blood pressure through the vascular smooth muscle GLP-1 receptor. | Semaglutide | animal | 2026-04-22 |
| ANIMAL | evidence | Optimized sublingual delivery of dual fatty acid-conjugated GLP-1 receptor agonist TE-8105 produces durable efficacy in diabetic mice. | Semaglutide | Glycemic control · animal | 2026-04-10 |
| ANIMAL | evidence | Early intervention with tirzepatide or semaglutide influences anti-atherosclerotic effects in ApoE knockout mice. | Semaglutide | Glycemic control · animal | 2026-04-07 |
| ANIMAL | evidence | Molecular Characterization of the Effect of Glucagon-Like Peptide-1 Receptor Agonist Semaglutide in the Nephrotoxic Serum Nephritis Mouse Model. | Semaglutide | Kidney function · animal | 2026-04-01 |
| ANIMAL | evidence | Semaglutide restores metabolic and structural homeostasis along the gut-heart-metabolic axis in a cafeteria diet-induced obesity model. | Semaglutide | Weight & fat loss · animal | 2026-03-23 |
| ANIMAL | evidence | Semaglutide alleviates ovarian ferroptosis in polycystic ovary syndrome and is associated with reduced GPX4 promoter hypermethylation. | Semaglutide | animal | 2026-03-10 |
| ANIMAL | evidence | Semaglutide attenuates diabetic vascular calcification by enhancing autophagy and lysosomal function via targeting CPNE1. | Semaglutide | animal | 2026-03-07 |
| ANIMAL | evidence | Complementary neuroprotective effects of semaglutide and papaya in diabetic encephalopathy via antioxidant and insulin-signaling pathways. | Semaglutide | Glycemic control · animal | 2026-03-06 |
| ANIMAL | evidence | Physical activity promotes gut adaptation, nutrient responsiveness, and sensitivity to gut peptides in male mice. | NNC0113-0217 | Gut barrier & GI healing · animal | 2026-03-01 |
| ANIMAL | evidence | D-Allulose Reduces Weight More Persistently than Oral Semaglutide While Both Equally Elevate Grip Strength in Diet-Induced Obese Mice. | Semaglutide | Weight & fat loss · animal | 2026-02-23 |
| ANIMAL | evidence | The NLRP3 inhibitor NT-0796 enhances and sustains GLP-1R agonist-mediated weight loss in a murine diet-induced obesity model. | Wegovy | Weight & fat loss · animal | 2025-07-01 |
| ANIMAL | evidence | Anorexigenic and anti-inflammatory signaling pathways of semaglutide via the microbiota-gut--brain axis in obese mice. | Ozempic | Inflammation · animal | 2025-02-01 |
| ANIMAL | evidence | Effects of semaglutide-loaded lipid nanocapsules on metabolic dysfunction-associated steatotic liver disease. | Rybelsus | animal | 2024-10-01 |
| ANIMAL | evidence | Reversal of High Fat Diet-Induced Obesity, Systemic Inflammation, and Astrogliosis by the NLRP3 Inflammasome Inhibitors NT-0249 and NT-0796. | Wegovy | Weight & fat loss · animal | 2024-02-15 |
| PRECLINICAL | evidence | A qualitative study exploring experiences about using semaglutide for weight loss in a rural setting in Denmark - 'she is probably on the meds'. | Semaglutide | Weight & fat loss | 2026-12-01 |
| PRECLINICAL | evidence | Annual pharmacy cost per patient achieving composite treatment endpoints: a cost to target analysis of tirzepatide versus subcutaneous semaglutide 1 mg in patients with type 2 diabetes in the UK. | Semaglutide | Glycemic control | 2026-12-01 |
| PRECLINICAL | evidence | GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers. | Semaglutide | Glycemic control | 2026-12-01 |
| PRECLINICAL | evidence | Hydrophobic ion pairing formed semaglutide designed for oral self-microemulsifying delivery in diabetes treatment. | Semaglutide | Glycemic control | 2026-09-01 |
| PRECLINICAL | evidence | Obstetrical and medical outcomes following GLP-1 receptor agonist exposure in pregnancy: a case series. | Semaglutide | — | 2026-09-01 |
| PRECLINICAL | evidence | Micronutrient risk with GLP-1 receptor and dual incretin agonists in obesity: Mechanistic pathways, clinical signals, and a monitoring framework. | Semaglutide | — | 2026-09-01 |
| PRECLINICAL | evidence | GLP-1 receptor agonists in ADPKD: from metabolic rationale to phenotype-enriched translational testing. | Semaglutide | — | 2026-09-01 |
| PRECLINICAL | evidence | Direct effects of glucagon-like Peptide-1 receptor agonists on mitochondrial function in human-derived in vitro models: A systematic review and meta-analysis. | Semaglutide | — | 2026-09-01 |
| PRECLINICAL | evidence | Changes in food cravings, dietary quality, body composition, and dietary intake during GLP-1 receptor agonist therapy: The CRAVE study. | Semaglutide | — | 2026-09-01 |